{"prompt": "['CONFIDENTIAL', 'Protocol ANB019-002 - Amendment 5', 'TABLE OF CONTENTS', 'INVESTIGATOR SIGNATURE PAGE:', '3', 'TABLE OF CONTENTS', '4', 'TABLE OF TABLES', '7', '1.0', 'PROTOCOL SUMMARY', '8', '1.1', 'Synopsis', '8', '1.2', 'Study Schema', '12', '1.3', 'Schedule of Activities', '13', '2.0', 'INTRODUCTION', '16', '2.1', 'Study Rationale', '16', '2.2', 'Background', '17', '2.2.1', 'Nonclinical Studies', '17', '2.2.2', 'Clinical Studies', '18', '2.3', 'Benefit/Risk Assessment', '19', '3.0', 'OBJECTIVES AND ENDPOINTS', '22', '4.0', 'STUDY DESIGN', '24', '4.1', 'Overall Design', '24', '4.2', 'Scientific Rationale for Study Design', '25', '4.3', 'Justification for Dose', '25', '4.4', 'End of Study Definition', '25', '4.5', 'Study Stopping Criteria', '25', '4.5.1', 'Stopping Criteria for Individual Subjects', '25', '4.5.2', 'Criteria for Stopping the Study', '26', '5.0', 'STUDY POPULATION', '27', '5.1', 'Inclusion Criteria', '27', '5.2', 'Exclusion Criteria', '28', '5.3', 'Lifestyle Considerations', '30', '5.4', 'Screen Failures', '30', '6.0', 'STUDY TREATMENT', '32', '6.1', 'Study Treatment Administered', '32', '6.2', 'Preparation/Handling/Storage/Accountability', '33', '6.3', 'Measures to Minimize Bias: Randomization and Blinding', '34', '6.4', 'Study Treatment Compliance', '34', '6.5', 'Concomitant Therapy', '34', '29 October 2019', '4']['CONFIDENTIAL', 'Protocol ANB019-002 - Amendment 5', '6.5.1', 'Rescue Medicine', '35', '6.6', 'Dose Modification', '35', '6.7', 'Treatment After the End of the Study', '35', '7.0', 'DISCONTINUATION OF STUDY TREATMENT AND SUBJECT', 'ISCONTINUATION/WITHDRAWAL', '36', '7.1', 'Discontinuation of Study Treatment', '36', '7.1.1', 'Temporary Interruption', '36', '7.1.2', 'Re-challenge', '36', '7.2', 'Subject Discontinuation/Withdrawal from the Study', '36', '7.3', 'Lost to Follow-up', '37', '8.0', 'STUDY ASSESSMENTS AND PROCEDURES', '38', '8.1', 'Efficacy Assessments', '38', '8.1.1', 'Clinical Global Impression', '38', '8.1.2', 'Modified Japanese Dermatology Association (JDA) Severity', 'Index', '38', '8.1.3', 'Psoriasis Area Severity Index (Only in Subjects With PP)', '39', '8.1.4', \"Generalized Pustular Psoriasis Physician's Global\", 'Assessment Scale', '39', '8.1.5', 'Dermatology Life Quality Index', '39', '8.2', 'Safety', 'Assessments', '39', '8.2.1', 'Physical Examinations', '39', '8.2.2', 'Chest X-ray', '40', '8.2.3', 'Height and Weight', '40', '8.2.4', 'Vital Signs', '40', '8.2.5', 'Electrocardiograms', '40', '8.2.6', 'Photography', '40', '8.2.7', 'Clinical Safety Laboratory Assessments', '41', '8.2.8', 'Telephone Contact', '41', '8.3', 'Adverse Events', '41', '8.3.1', 'Time Period and Frequency for Collecting AE and SAE', 'Information', '42', '8.3.2', 'Method of Detecting AEs and SAEs', '42', '8.3.3', 'Follow-up of AEs and SAEs', '42', '8.3.4', 'Regulatory Reporting Requirements for SAEs', '42', '8.3.5', 'Pregnancy', '43', '8.3.6', 'Adverse Events of Special Interest', '43', '8.3.7', 'Infusion-related Adverse Events', '43', '8.3.8', 'Disease-related Events and/or Disease-related Outcomes Not', 'Qualifying as AEs or SAEs', '44', '8.4', 'Treatment of Overdose', '44', '8.5', 'Pharmacokinetics', '45', '8.6', 'Pharmacodynamics', '46', '8.7', 'Genetics', '46', '8.8', 'Biomarkers', '46', '29 October 2019', '5']\n\n###\n\n", "completion": "END"}